Induction chemotherapy followed by radiotherapy for N3 head and neck squamous cell carcinoma
Chengrun Du MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Search for more papers by this authorPierre Blanchard MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Université Paris Sud, Kremlin-Bicêtre, France
Molecular Radiotherapy, INSERM 1030, Villejuif, France
Search for more papers by this authorCaroline Even MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorAngela Boros MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorPhilippe Gorphe MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorIngrid Breuskin MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorNeus Baste-Rotllan MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorFrance Nguyen MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorAmandine Ruffier MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorFrançois Bidault MD
Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorCamélia Billard MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorFrançois Janot MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorHaitham Mirghani MD
Department of ENT and head neck surgery, Hopital Europeen George Pompidou, Paris, France
Search for more papers by this authorStephane Temam MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorCorresponding Author
Yungan Tao MD, PhD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Université Paris Sud, Kremlin-Bicêtre, France
Molecular Radiotherapy, INSERM 1030, Villejuif, France
Correspondence
Yungan Tao MD, PhD, Department of Radiation Oncology, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805 Villejuif France.
Email: [email protected]
Search for more papers by this authorChengrun Du MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Search for more papers by this authorPierre Blanchard MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Université Paris Sud, Kremlin-Bicêtre, France
Molecular Radiotherapy, INSERM 1030, Villejuif, France
Search for more papers by this authorCaroline Even MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorAngela Boros MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorPhilippe Gorphe MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorIngrid Breuskin MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorNeus Baste-Rotllan MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorFrance Nguyen MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorAmandine Ruffier MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorFrançois Bidault MD
Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorCamélia Billard MD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorFrançois Janot MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorHaitham Mirghani MD
Department of ENT and head neck surgery, Hopital Europeen George Pompidou, Paris, France
Search for more papers by this authorStephane Temam MD
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Search for more papers by this authorCorresponding Author
Yungan Tao MD, PhD
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Université Paris Sud, Kremlin-Bicêtre, France
Molecular Radiotherapy, INSERM 1030, Villejuif, France
Correspondence
Yungan Tao MD, PhD, Department of Radiation Oncology, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805 Villejuif France.
Email: [email protected]
Search for more papers by this authorFunding information: China Scholarship Council, Grant/Award Number: 201806105003
Abstract
Background
The treatment outcomes for N3 HNSCC treated with induction chemotherapy (ICT) followed by definitive radiation were reported to clarify the role of ICT and potential prognostic factors.
Methods
A retrospective study was conducted on 120 patients with N3 (≥6 cm) HNSCC, who were treated with ICT as initial treatment. Survival outcomes and potential prognostic factors were reported.
Results
The response rate to ICT was 68.3%. There was a statistically significant difference between responders and non-responders in terms of 5-year OS (35.1% vs 13.3%, P < .001) and PFS (29.4% vs 7.4%, P < .001). Good response to ICT (P < .001) and upfront neck dissection (UFND) before radiotherapy (P = .016) were factors predicting for better OS. However, UFND before radiotherapy was not associated with improved outcomes among responders.
Conclusions
This study suggests that ICT could be one treatment option for N3 HNSCC. Among responders to ICT, UFND before radiotherapy could be avoided.
Supporting Information
| Filename | Description |
|---|---|
| hed26021_sup-0001-TableS1.docxWord 2007 document , 21.1 KB | Table S1 Univariate and multivariate analyses of factors associated with local recurrence free survival and regional recurrence free survival |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Tao Y, Daly-Schveitzer N, Lusinchi A, Bourhis J. Advances in radiotherapy of head and neck cancers. Curr Opin Oncol. 2010; 22: 194-199.
- 2Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92: 4-14.
- 3Ballonoff A, Raben D, Rusthoven KE, et al. Outcomes of patients with n3 neck nodes treated with chemoradiation. Laryngoscope. 2008; 118: 995-998.
- 4Haddad RI, Posner M, Hitt R, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018; 29: 1130-1140.
- 5Lorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011; 12: 153-159.
- 6Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357: 1695-1704.
- 7Blanchard P, Bourhis J, Lacas B, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013; 31: 2854-2860.
- 8Geoffrois L, Martin L, De Raucourt D, et al. Induction chemotherapy followed by Cetuximab radiotherapy is not superior to concurrent Chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007–02 phase III randomized trial. J Clin Oncol. 2018:JCO2017762591.
- 9Cohen EE, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014; 32: 2735-2743.
- 10Pitman KT, Bradley PJ. Management of the N3 neck. Curr Opin Otolaryngol Head Neck Surg. 2003; 11: 129-133.
- 11Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355: 949-955.
- 12Tao Y, Auperin A, Graff P, et al. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: pooled analysis of two GORTEC randomized trials. Oral Oncol. 2017; 71: 61-66.
- 13Hartl DM, Brasnu DF. Chemotherapy alone for glottic carcinoma: a need for higher-level evidence. Ann Otol Rhinol Laryngol. 2009; 118: 543-545.
- 14Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996; 88: 890-899.
- 15Marur S, Li S, Cmelak AJ, et al. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly Cetuximab in patients with HPV-associated Resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN cancer research group. J Clin Oncol. 2017; 35: 490-497.
- 16Mehanna H, Wong WL, McConkey CC, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med. 2016; 374: 1444-1454.
- 17Elicin O, Nisa L, Dal Pra A, et al. Up-front neck dissection followed by definitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: rationale, complications, toxicity rates, and oncological outcomes - a systematic review. Radiother Oncol. 2016; 119: 185-193.
- 18Ioannidis JPA. The proposal to lower P value thresholds to .005. JAMA. 2018; 319: 1429-1430.
- 19Tao Y, Geoffrois L, Martin L, et al. Impact of p16 expression on induction taxotere-cisplatin-5 FU (TPF) followed by cetuximab-radiotherapy in N2b-N3 head and neck squamous cell carcinoma (HNSCC): results of GORTEC 2007-02 phase III randomized trial. J Clin Oncol. 2017; 35(15_suppl): 6070.
Citing Literature
